Loading…
Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction
OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical,...
Saved in:
Published in: | Diabetes spectrum 2020-11, Vol.33 (4), p.299-306 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83 |
---|---|
cites | cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83 |
container_end_page | 306 |
container_issue | 4 |
container_start_page | 299 |
container_title | Diabetes spectrum |
container_volume | 33 |
creator | Jayakumari, Chellamma Jabbar, Puthiyaveettil Khadar Soumya, Sarayu Jayakumar, R.V. Das, Darvin Vamadevan Girivishnu, Gopi Gopi, Anjana Gomez, Ramesh Sreenath, Ravindranath Nair, Abilash |
description | OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed. |
doi_str_mv | 10.2337/ds19-0046 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7666608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2464865040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</originalsourceid><addsrcrecordid>eNpdkU1LJDEQhoMo6qoH_0HAi3voNV-dTO9hQUZ3FQYUHfEYMknFifZ0ZpNuQX-9aRRB65BKJU9eqvIidEjJL8a5OnGZNhUhQm6gXdoIUSle882yJ4JUDZX1DvqR8yMhhFHGttEO54xxJdUuep2FdXD4OkUfWsChw5edC6bD16YP0PUZ34d-iecva8AMnwWzgB7ybzxfAr61sZz6mPBpv4QUs23L2geLpya5EJ9NtkNrUnmWwWTANyE_4Rtwg-1D7PbRljdthoOPvIfu_p7PpxfV7Orf5fR0VlnW1LISglLfeEoJEEe5rb30XBIlvLOOEDUxBkrJnVwslBA1V8w2paydMNy5Cd9Df95118NiBc6WqZJp9TqFlUkvOpqgv950Yakf4rNWsgQZBY4_BFL8P0Du9SpkC21rOohD1kzI0hDlTV3Qo2_oYxxSV8YbKTGRdbGkUD_fKVs-LSfwn81QokdH9eioHh3lbwP7kjI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2464865040</pqid></control><display><type>article</type><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><source>PubMed Central</source><creator>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</creator><creatorcontrib>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</creatorcontrib><description>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</description><identifier>ISSN: 1040-9165</identifier><identifier>EISSN: 1944-7353</identifier><identifier>DOI: 10.2337/ds19-0046</identifier><identifier>PMID: 33223767</identifier><language>eng</language><publisher>Alexandria: American Diabetes Association</publisher><subject>Arteriosclerosis ; Atherosclerosis ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Dyslipidemia ; High density lipoprotein ; Hyperlipidemia ; Lipids ; Low density lipoprotein ; Metabolic disorders ; Patients ; Statins ; Thyroid</subject><ispartof>Diabetes spectrum, 2020-11, Vol.33 (4), p.299-306</ispartof><rights>Copyright American Diabetes Association Nov 1, 2020</rights><rights>2020 by the American Diabetes Association 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</citedby><cites>FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</cites><orcidid>0000-0001-6776-1582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666608/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666608/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Jayakumari, Chellamma</creatorcontrib><creatorcontrib>Jabbar, Puthiyaveettil Khadar</creatorcontrib><creatorcontrib>Soumya, Sarayu</creatorcontrib><creatorcontrib>Jayakumar, R.V.</creatorcontrib><creatorcontrib>Das, Darvin Vamadevan</creatorcontrib><creatorcontrib>Girivishnu, Gopi</creatorcontrib><creatorcontrib>Gopi, Anjana</creatorcontrib><creatorcontrib>Gomez, Ramesh</creatorcontrib><creatorcontrib>Sreenath, Ravindranath</creatorcontrib><creatorcontrib>Nair, Abilash</creatorcontrib><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><title>Diabetes spectrum</title><description>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</description><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Dyslipidemia</subject><subject>High density lipoprotein</subject><subject>Hyperlipidemia</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Metabolic disorders</subject><subject>Patients</subject><subject>Statins</subject><subject>Thyroid</subject><issn>1040-9165</issn><issn>1944-7353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LJDEQhoMo6qoH_0HAi3voNV-dTO9hQUZ3FQYUHfEYMknFifZ0ZpNuQX-9aRRB65BKJU9eqvIidEjJL8a5OnGZNhUhQm6gXdoIUSle882yJ4JUDZX1DvqR8yMhhFHGttEO54xxJdUuep2FdXD4OkUfWsChw5edC6bD16YP0PUZ34d-iecva8AMnwWzgB7ybzxfAr61sZz6mPBpv4QUs23L2geLpya5EJ9NtkNrUnmWwWTANyE_4Rtwg-1D7PbRljdthoOPvIfu_p7PpxfV7Orf5fR0VlnW1LISglLfeEoJEEe5rb30XBIlvLOOEDUxBkrJnVwslBA1V8w2paydMNy5Cd9Df95118NiBc6WqZJp9TqFlUkvOpqgv950Yakf4rNWsgQZBY4_BFL8P0Du9SpkC21rOohD1kzI0hDlTV3Qo2_oYxxSV8YbKTGRdbGkUD_fKVs-LSfwn81QokdH9eioHh3lbwP7kjI</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Jayakumari, Chellamma</creator><creator>Jabbar, Puthiyaveettil Khadar</creator><creator>Soumya, Sarayu</creator><creator>Jayakumar, R.V.</creator><creator>Das, Darvin Vamadevan</creator><creator>Girivishnu, Gopi</creator><creator>Gopi, Anjana</creator><creator>Gomez, Ramesh</creator><creator>Sreenath, Ravindranath</creator><creator>Nair, Abilash</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6776-1582</orcidid></search><sort><creationdate>20201101</creationdate><title>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</title><author>Jayakumari, Chellamma ; Jabbar, Puthiyaveettil Khadar ; Soumya, Sarayu ; Jayakumar, R.V. ; Das, Darvin Vamadevan ; Girivishnu, Gopi ; Gopi, Anjana ; Gomez, Ramesh ; Sreenath, Ravindranath ; Nair, Abilash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Dyslipidemia</topic><topic>High density lipoprotein</topic><topic>Hyperlipidemia</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Metabolic disorders</topic><topic>Patients</topic><topic>Statins</topic><topic>Thyroid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayakumari, Chellamma</creatorcontrib><creatorcontrib>Jabbar, Puthiyaveettil Khadar</creatorcontrib><creatorcontrib>Soumya, Sarayu</creatorcontrib><creatorcontrib>Jayakumar, R.V.</creatorcontrib><creatorcontrib>Das, Darvin Vamadevan</creatorcontrib><creatorcontrib>Girivishnu, Gopi</creatorcontrib><creatorcontrib>Gopi, Anjana</creatorcontrib><creatorcontrib>Gomez, Ramesh</creatorcontrib><creatorcontrib>Sreenath, Ravindranath</creatorcontrib><creatorcontrib>Nair, Abilash</creatorcontrib><collection>CrossRef</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes spectrum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayakumari, Chellamma</au><au>Jabbar, Puthiyaveettil Khadar</au><au>Soumya, Sarayu</au><au>Jayakumar, R.V.</au><au>Das, Darvin Vamadevan</au><au>Girivishnu, Gopi</au><au>Gopi, Anjana</au><au>Gomez, Ramesh</au><au>Sreenath, Ravindranath</au><au>Nair, Abilash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction</atitle><jtitle>Diabetes spectrum</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>33</volume><issue>4</issue><spage>299</spage><epage>306</epage><pages>299-306</pages><issn>1040-9165</issn><eissn>1944-7353</eissn><abstract>OBJECTIVE Reduction of atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes requires proper management of lipid parameters. This study aimed to find the pattern of dyslipidemia and scope of ASCVD risk reduction in patients with diabetes by lipid management. METHODS Clinical, biochemical, and medication profiles of all patients with diabetes attending a tertiary diabetes care hospital over a 2-year period were collected. The prevalence of various lipid abnormalities was determined after excluding patients with thyroid dysfunction and those on lipid-lowering medications. Patients were stratified according to LDL cholesterol, HDL cholesterol, and triglyceride levels, and other clinical parameters were compared among the groups. The adequacy of statin treatment was assessed based on American Diabetes Association guidelines. RESULTS Nine hundred and seventy-one patients were included. The prevalence of hyperlipidemia was 40.0%, of whom 14.6% were newly diagnosed. The most common lipid abnormality was elevated LDL cholesterol. Higher A1C and fasting blood glucose values were found to be associated with higher LDL cholesterol levels. Twenty-seven percent of patients with indications for treatment with statins were receiving them. Of those being treated with statins, 42.6% had an LDL cholesterol level ≥100 mg/dL. CONCLUSION In South Indian patients with type 2 diabetes and fair glycemic control, high LDL cholesterol is the predominant lipid abnormality. There remains a huge potential for ASCVD risk reduction in this population if the knowledge practice gap is addressed.</abstract><cop>Alexandria</cop><pub>American Diabetes Association</pub><pmid>33223767</pmid><doi>10.2337/ds19-0046</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6776-1582</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1040-9165 |
ispartof | Diabetes spectrum, 2020-11, Vol.33 (4), p.299-306 |
issn | 1040-9165 1944-7353 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7666608 |
source | PubMed Central |
subjects | Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Cholesterol Diabetes Diabetes mellitus (non-insulin dependent) Dyslipidemia High density lipoprotein Hyperlipidemia Lipids Low density lipoprotein Metabolic disorders Patients Statins Thyroid |
title | Lipid Profile in Indian Patients With Type 2 Diabetes: The Scope for Atherosclerotic Cardiovascular Disease Risk Reduction |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A55%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Profile%20in%20Indian%20Patients%20With%20Type%202%20Diabetes:%20The%20Scope%20for%20Atherosclerotic%20Cardiovascular%20Disease%20Risk%20Reduction&rft.jtitle=Diabetes%20spectrum&rft.au=Jayakumari,%20Chellamma&rft.date=2020-11-01&rft.volume=33&rft.issue=4&rft.spage=299&rft.epage=306&rft.pages=299-306&rft.issn=1040-9165&rft.eissn=1944-7353&rft_id=info:doi/10.2337/ds19-0046&rft_dat=%3Cproquest_pubme%3E2464865040%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2956-4411f9f110e0d13c5f6f36074fdcd0078aae6073d6bb7445372c973d5d4a3dd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2464865040&rft_id=info:pmid/33223767&rfr_iscdi=true |